U.S. markets open in 1 hour 11 minutes
  • S&P Futures

    3,330.50
    -52.50 (-1.55%)
     
  • Dow Futures

    26,870.00
    -495.00 (-1.81%)
     
  • Nasdaq Futures

    11,437.00
    -151.00 (-1.30%)
     
  • Russell 2000 Futures

    1,557.90
    -31.10 (-1.96%)
     
  • Crude Oil

    37.73
    -1.84 (-4.65%)
     
  • Gold

    1,887.00
    -24.90 (-1.30%)
     
  • Silver

    23.92
    -0.65 (-2.67%)
     
  • EUR/USD

    1.1729
    -0.0061 (-0.52%)
     
  • 10-Yr Bond

    0.7780
    0.0000 (0.00%)
     
  • Vix

    36.80
    +4.34 (+13.37%)
     
  • GBP/USD

    1.2952
    -0.0090 (-0.69%)
     
  • USD/JPY

    104.3670
    -0.1270 (-0.12%)
     
  • BTC-USD

    13,343.21
    -366.81 (-2.68%)
     
  • CMC Crypto 200

    263.56
    +2.27 (+0.87%)
     
  • FTSE 100

    5,627.64
    -101.35 (-1.77%)
     
  • Nikkei 225

    23,418.51
    -67.29 (-0.29%)
     

DTx Pharma to Present at the Virtual 7th Solebury Trout Fall Private Company Showcase

·2 mins read

SAN DIEGO, Oct. 5, 2020 /PRNewswire/ -- DTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease, announced today that Arthur T. Suckow, Ph.D., CEO of DTx Pharma, will be presenting a company overview and will participate in 1x1 meetings at the Virtual 7th Solebury Trout Fall Private Company Showcase on Thursday, October 15th, 2020 at 12:00 pm PDT. The conference is co-hosted by BMO and Davis Polk and is being held in a virtual format.

About DTx Pharma

DTx Pharma, Inc. is a privately-held biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease. The company's proprietary delivery technology platform, FALCON (Fatty Acid Long Chain OligoNucleotide), utilizes fatty acids as targeting ligands to enable the delivery of oligonucleotide therapies to tissues and cell types throughout the body. In preclinical studies, DTx has demonstrated cellular uptake and broad activity of oligonucleotides in the retina, muscle, heart, neurons, T cells and many other specialized cell types. Based upon the novelty, IP position and data demonstrating the effectiveness of its proprietary fatty acid motifs, DTx has previously received investment, nondilutive funding and other forms of support from Eli Lilly, Eye CRO and the CMT Research Foundation (CMTRF) for its ocular and muscle programs and has received multiple grant awards from the NIH (NCATS, NIA), and the TPEP program of Alzheimer's Association and Rainwater Charitable Trust to advance its efforts to treat CNS diseases. To learn more about DTx Pharma, please visit www.dtxpharma.com and follow DTx on Twitter @DTxPharma.

Contact:

Amy Conrad
Juniper Point
858-366-3243
amy@juniper-point.com

Cision
Cision

View original content:http://www.prnewswire.com/news-releases/dtx-pharma-to-present-at-the-virtual-7th-solebury-trout-fall-private-company-showcase-301145810.html

SOURCE DTx Pharma